April 22, 2020


Virtual approaches to clinical research leverage digital technologies to relieve study sites of many, if not all, responsibilities of the research process—from identifying potential study subjects to screening them for eligibility to obtaining their consent for enrollment to entering their study data.

In this free webinar, the featured speaker will discuss how such approaches can empower patients by bringing the research process to them, as well as challenges that arise when doing so. Key themes in virtual research will be highlighted, including the latest trends, the differences among the various types of virtual research and their applications in the real-world setting, where stakeholders are already excited by the potential that virtual approaches can bring to clinical research.

About the Speaker

David Thompson, PhD is a health economist who has been working in the field of HEOR since 1988. During the course of his career, he has developed expertise in economic modeling, retrospective database analysis, prospective real-world research, and patient-reported outcomes.  His work has been global in nature, with extensive experience in North American & European markets as well as the emerging markets of the Asia-Pacific and Latin American regions.

Dave is Senior Vice President, Real-World Research, at Syneos Health, a position he has held since 2016. Prior to joining Syneos Health, he held leadership positions at Quintiles (2012-2016), i3 Innovus/OptumInsight (2000-2012) and PAI (1988-2000).

Dave is a long-time contributor to ISPOR, having led the launch and functioned as Editor-in-Chief of Value & Outcomes Spotlight (and, before it, ISPOR Connections) from 2008 to the present.

Among various current external affiliations, Dave is a steering committee member for the Clinical Trials Transformation Initiative (CTTI), a multi-stakeholder initiative of Duke University and the US Food & Drug Administration; a team leader on the CTTI initiatives on real-world evidence (RWE) and pragmatic clinical trials; and an advisory group member for the Duke-Margolis Real-World Evidence Collaborative.


For more information on this topic, download our report below..